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Abstract Alzheimer’s disease (AD) is a neurodegenerative
condition that leads to neuronal death and memory dysfunc-
tion. In the past, specific peroxisome proliferator-activated
receptor (PPAR)γ-agonists, such as pioglitazone, have been
tested with limited success to improve AD pathology. Here,
we investigated the therapeutic efficacy of GFT1803, a novel
potent PPAR agonist that activates all the three PPAR iso-
forms (α/δ/γ) in the APP/PS1 mouse model in comparison to
the selective PPARγ-agonist pioglitazone. Both compounds
showed similar brain/plasma partitioning ratios, although
whole body and brain exposure to GFT1803 was significantly
lower as compared to pioglitazone, at doses used in this study.
Oral treatment of APP/PS1 mice with GFT1803 decreased
microglial activation, amyloid β (Aβ) plaque area, Aβ levels
in sodium dodecyl sulfate- and formic acid-soluble fractions
in a concentration-dependent manner. With a single exception
of Aβ38 and Aβ40 levels, measured by ELISA, these effects
were not observed in mice treated with pioglitazone. Both
ligands decreased glial fibrillary acidic protein (GFAP) ex-
pression to similar extent and did not affect ApoE expression.
Finally, GFT1803 increased insulin-degrading enzyme ex-
pression. Analysis of spatial memory formation in the Morris
water maze demonstrated that both compounds were able to
partially revert the phenotype of APP/PS1mice in comparison
to wild-type mice with GFT1803 being most effective. As
compared to pioglitazone, GFT1803 (pan-PPAR agonist) pro-
duced both quantitatively superior and qualitatively different
therapeutic effects with respect to amyloid plaque burden,
insoluble Aβ content, and neuroinflammation at significantly
lower whole body and brain exposure rates.
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Alzheimer’s disease is clinically characterized by progressive
memory loss and decline of cognitive functions. Besides the
classical histopathological hallmarks, extracellular amyloid β
(Aβ) deposition and neurofibrillary tangles of tau protein,
neuroinflammation has been established as a major compo-
nent [1]. Aβ derives from a larger precursor protein (APP)
by subsequent cleavages by two aspartyl proteases, [beta]-site
APP cleaving enzyme 1 (BACE1) andγ-secretase, resulting in
the secretion of Aβ into the brain parenchyma [1]. Deposition
of Aβ has been suggested to initiate the pathological sequalae
which ultimately leads to the development of Alzheimer’s
disease (AD) [2]. Additionally, oligomeric, soluble Aβ
causes cellular toxicity and interferes with memory forma-
tion at the synapse thereby causing the observed memory
loss [3, 4]. Therefore, strategies that interfere with the forma-
tion and deposition of Aβ or accelerate its removal hold
therapeutic promise.
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Although there is currently no curative treatment for AD
patients, a number of epidemiological studies demonstrated
that a sustained intake of several non-steroidal anti-
inflammatory drugs (NSAIDs) reduces AD risk by as much
as 80% and delays its onset [5]. NSAIDs are mostly known as
cyclooxygenase inhibitors, preventing prostaglandin and
thromboxane synthesis from arachidonic acid, but additional
cyclooxygenase-unrelated activities, such as binding to
prostaglandin receptors, modulation of γ-secretase activity
and activation of the peroxisomal proliferator receptor γ
(PPARγ), a member of the nuclear hormone receptor super-
family, seem to be involved in AD prevention. Regarding the
latter, it was rapidly suggested that protective effects arise from
the ability of NSAIDs to ligate PPARγ and to inhibit neuroin-
flammation in the AD brain [6]. Of note, among different
NSAIDs, indomethacin and ibuprofen were characterized as
PPARγ agonists with anti-inflammatory properties [7]. PPARγ
is expressed in cells of the myeloid lineage including macro-
phages and microglia and its activation inhibits nuclear factor
kappa-light-chain-enhancer (NFκB), AP-1, and STAT-1-
dependent signal transduction pathways, thereby suppressing
key inflammatory cytokines, such as TNF-α, IL-1β, and Il-6
[8, 9].
The development of more specific ligands of PPARγ,
namely the thiazolidinedione (TZD) class of oral antidiabetics
has prompted experimental studies to further validate PPARγ-
mediated neuroprotection in models of cerebral ischemia,
Parkinson’s disease (PD), amyotrophic lateral sclerosis, and
AD [10]. A preventive effect of the TZD pioglitazone on
sodium dodecylsulfate (SDS)-soluble Aβ40 accumulation
[11] as well as on micro- and astroglial activation and Aβ
plaque burden [12] was shown in two different murine AD
models, Tg2576 mice and APPV717I mice, respectively.
Besides the Aβ-lowering effect, PPAR agonists have also
been shown to suppress Aβ-mediated activation of microglia
and prevented cortical or hippocampal neuronal cell death
in vitro [13–15]. Mechanistically, PPARγ has been shown to
affect Aβ metabolism by suppressing the immunostimulated
BACE1 promoter via a PPAR response element [16, 17]
thereby lowering BACE1 protein levels and, as a consequence,
Aβ production.
Due to a number of side effects and adverse clinical obser-
vations, TZDs of the pioglitazone generation recently came
under scrutiny, followed by the development of a further class
of PPAR agonists, which activate not only PPARγ but also the
two other isoforms, PPARα and PPARδ. The use of those
pan-PPAR agonists is appealing since it has been reported
that, in contrast to PPARγ, the expression of PPARα and
PPARδ is reduced in AD brains [18]. PPARα function insuf-
ficiency may predispose neural tissue and cerebral microvas-
culature to exacerbated oxidative stress, since PPARα activa-
tion by fenofibrate and other agonists attenuates vascular
damage through inhibition of lipotoxicity, inflammation, and
reactive oxygen species [19]. Likewise, PPARδwas examined
for possible neuroprotective effects. Using synthetic PPARδ-
specific agonists neuroprotective effects have been observed
in animal models of cerebral ischemia, multiple sclerosis, AD,
PD, radiation-induced brain injury, and spinal cord injury
[20–24].
In this study, we investigated the efficacy of GFT1803, a
novel, experimental pan-PPAR agonist on amyloid burden,




Age-matched, female APP/PS1 transgenic animals (# 005864,
The Jackson Laboratory) [25] were on C57/Bl6 genetic back-
ground. Mice were mice fed on a normal mouse chow or on
chow containing either 1 or 10 mg/kg GFT1803 or 50 mg/kg
pioglitazone from 4 to 6 months of age. Mice numbers were
n=12 for 1 and 10 mg/kg GFT1803, n=11 for APP/PS1, and
n=10 for 50mg/kg pioglitazone. For pharmacokinetic studies,
Swiss mice (Elevage Janvier, France) were used. Mice were
housed under standard conditions at 22 °C and a 12-h light–
dark cycle with free access to food and water. Animal care and
handling was performed according to the declaration of
Helsinki and approved by the local ethical committees.
Gal4-PPAR Activation Assays
COS-7 cells were maintained in standard culture conditions
(Dulbecco’s modified Eagle's minimal medium (DMEM))
supplemented with 10 % fetal calf serum, 1 % sodium pyru-
vate, 1 % essential amino acids, and 1 % streptomycin/
penicillin at 37 °C in a humidified atmosphere of 5 % CO2.
All tested compounds were dissolved in DMSO (Sigma-
Aldrich). Cells were transfected using 2 μl JetPEITM
(Polyplus transfection)/μg of DNA. Briefly, 40 μg of
DNA was transfected in a 225-cm2 culture flask of adherent
COS-7 cells (respecting the 1:50 ratio between the
Gal4(RE)_TkpGL3 plasmid and the plasmid coding the
nuclear receptor of interest (pGal4-hPPARα, pGal4-
hPPARγ, pGal4-hPPARδ, pGal4-mPPARα, pGal4-
mPPARγ, and pGal4-mPPARδ) or of the pGal4phi plasmid
(negative control). Cells were seeded in 384-well plates at
the density of 20,000 cells/well and then incubated for 4 h
at 37 °C. The activation was performed by using the
Genesis Freedom 200™ robotic unit (Tecan), in fresh medium
supplemented with 2 % of synthetic serum, free of lipids
(Ultroser™, Biosepra) supplemented with the tested com-
pounds (compound of interest or reference molecules) or
vehicle (DMSO 0.1 %). Luciferase activity was measured
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using the Steady-Glo Luciferase Assay System (Promega,
Madison, WI, USA). All transactivation experiments were
performed at least two times. Activation curves were realized
using SigmaPlot (version 7.0 from SPSS, IBM) software.
SigmaPlot was also used to fit the standard curves and then
determine the specific EC50 values, maximum effect versus
reference molecules and Hill slope. The Emax effect of
GFT1803 was calculated relative to the maximal induction
(plateau) obtained with the corresponding reference com-
pound. The reference compounds for PPARα, PPARγ, and
PPARδ were fenofibrate (100 μM), rosiglitazone (10 μM),
and GW501516 (1 μM), respectively.
Compound Pharmacokinetics Study in Mice
The compound was administered to 5-week-old, male Swiss
mice (Elevage Janvier, France) by the PO route in a solution
of 0.5 % methyl cellulose (Sigma-Aldrich; M0262) and
0.3 % Polysorbate 80 (Tween 80; Sigma-Aldrich P8074).
At the precise time point, blood samplings were done at the
retro-orbital sinus. Blood samples were collected into tubes
containing both lithium and heparin, centrifuged at
2,500 rpm at 4 °C, and plasma was collected. Individual
plasma aliquots were frozen at −20 °C (±5 °C) and stored
until analysis.
Animals were perfused with 7 ml cold saline; the brain
tissue was collected and frozen at −20 °C. The molecular and
daughter ions were selected for each molecule by direct infu-
sion into the MS-MS system. According to the expected
sensitivity, eight-point calibration standards (1, 5, 10, 50,
100, 500, 1,000, and 5,000 ng/ml) were run using standard
conditions which consist to liquid chromatography–tandem
mass spectrometry (LC-MS/MS) system with C18 column
after precipitation of the plasma proteins with acetonitrile
before the start of the analytical test. Calibration standards
were performed in each matrix (plasma and brain). Prior to
analysis, 100μl of each plasma sample wasmixed with 300μl
acetonitrile. Following protein precipitation, samples were
vortex mixed for 30 s, centrifuged for 5 min at 15,000 rpm
and the supernatant was removed. Analysis was performed
using LC/MS/MS determination according to previous ana-
lytical test results. Brains were homogenized with a potter
using water (1:1, (w/w)). Homogenate (100 μl) was mixed
with 100 μl of acetonitrile. The mixture was vortexed for 30 s
and centrifuged for 5 min at 15,000 rpm. Brain homogenate
supernatants were directly measured by LC/MS/MS using a
C18 Kromasil column and API4000 (Applied Biosystem) or
Quattro (Waters) mass spectrometer.
Brain Protein Extraction
Snap-frozen brain hemispheres were extracted as previously
described [26]. In addition, the SDS-insoluble pellet was
extracted with 70 % formic acid in water. Formic acid was
removed using a speed vac (Eppendorf), and the resulting
pellet was solubilized in 200 mM Tris–HCl, pH 7.5.
Tissue Preparation
After competition of the behavioral testing, mice were anes-
thetized using isoflurane and transcardially perfused with
15 ml phosphate-buffered saline. The brains were removed
from the skull. One hemisphere was immediately deep-frozen
for biochemical analysis, and the other was fixed in 4 %
paraformaldehyde.
ELISA
Quantitative determination of Aβ was performed using an
electrochemiluminescence ELISA for Aβ1-38, Aβ1-40, and
Aβ1-42 (Mesoscale). Samples SDS and formic acid (FA) frac-
tions were at east 20 times diluted in 1 % Tx-100, 25 mM
Tris–HCl pH 7.5, 150 mM NaCl.
Histology
Serial sagittal cryosections (40 μm, four sections per mouse)
were immunostained using antiserum against glial fibrillary
acidic protein (GFAP) (DAKO, 1:800), antibody IC16 [27]
against human Aβ1-15 (1:400), and rabbit polyclonal antise-
rum against Iba1 (WAKO, 1:200). For that, sections were
treated 15 min at 80 °C in 100 mM citrate buffer pH 5.5 and
afterwards with 50 % methanol for 10 min. Sections were
washed in phosphate-buffered saline (PBS), permeabilized
using PBST (PBST, 0.1 % Tx-100), and blocked for 1 h
in 20 % goat serum in PBST. Primary antibodies were
added in 20 % goat serum on PBST for 18 h at 4 °C
while gently rocking. Secondary antibodies were added in 20%
goat serum on PBST for 1.5 h at RT. Sections were mounted
with ImmuMount (Thermo Scientific, Bonn, Germany) on
Superfrost slides.
For methoxy-XO4 [28] staining, sections were rinsed in
PBS, incubated in 10 μM methoxy-XO4 in 40 % ethanol/
60 % H2O adjusted to pH 10 with 0.1 N NaOH for 10 min
at RT, washed three times with water, incubated for
2 min in 0.2 % NaOH in 80 % ethanol, and washed
three times with water. Sections were analyzed using a
BX61 microscope equipped with a disk scanning unit to
achieve confocality (Olympus, Hamburg, Germany). Image
stacks were deconvoluted using Cell^P (Olympus, Hamburg,
Germany). Quantitative assessment of plaque areas was
done using the MBF-ImageJ 1.43m software bundle
(NIH, Bethesda, MA, USA).
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Protein Blotting
Samples were separated by 4–12 % NuPAGE (Invitrogen)
using MES or MOPS buffer and transferred to nitrocellulose
membranes. APP, APP C-terminal fragments (CTF), and Aβ
were detected using antibody 6E10 (Covance) and the C-
terminal APP antibody 140 (CT15) [29], IDE using antibody
PC730 (Calbiochem), GFAP using anti-GFAP antiserum
Z0334 (Dako), ApoE using antibody sc-6384 (Sant Cruz),
and tubulin using antibody E7 (Developmental Studies
Hybridoma Bank). For dot blot analysis, 10 μl samples
containing 25 μM peptide were mixed with 200 μl PBS
and transferred to nitrocellulose membranes. Immunoreac-
tivity was detected by enhanced chemiluminescence reac-
tion (Millipore), and luminescence intensities were analyzed
using Chemidoc XRS documentation system (Biorad).
Open Field Behavior
The open field consisted of a 61×61×61 cm Perspex box with
dark walls and a white floor and was dimly illuminated. The
open field was virtually divided into corridors along the walls
(10 cm wide), corners (10×10 cm), and a center (40×40 cm).
Mice were put in the middle of the open field. The mice were
tracked for 5 min on three subsequent days using Ethovision
software (Noldus, Wageningen, The Netherlands).
Morris Water Maze
The Morris water maze used consisted of a 61-cm high plastic
circular basin (diameter 1 m) approximately half-filled with
water, with an invisible platform of 10×10 cm just under
water in the middle of one of four equal virtual segments
(quadrants). A white curtain surrounded the basin. Three
asymmetrically applied intra-maze cues were presented to
the animals. The water was made opaque using white disper-
sion color. Themice were subjected to one training session per
day for eight consecutive days. One training session consisted
of four trials of 40 s each. Time between trials was 10 s. The
starting position in each trial was quasi-random. If a mouse
did not succeed, it was put onto the platform for 15 s. On day
9, mice were put in the basin in the absence of the platform
and the time spend in the quadrants was determined (probe
trial). Mice were tracked using Ethovision software (Noldus,
Wageningen, The Netherlands).
Data Analysis
Results were expressed as mean ±SEM of at least three
experiments. For normally distributed samples, Student’s t test
was used for single comparisons of means and one-way
ANOVA for multiple comparisons of means combined with
the Tukey post test to evaluate statistical significance. The
levels for statistical significance were *p<0.05, **p<0.01,
and ***p<0.001. All evaluations were conducted using Prism
5.03 (Graphpad, San Diego, CA, USA).
Results
GFT1803 is a Potent and Equilibrated Pan-PPAR Compound
with a Significant Brain Penetration
GFT1803 is a diphenyl propane derivative and was designed to
activate all mouse and human PPAR isoforms (α, δ, and γ)
with comparable affinities and with moderate efficacy, as com-
pared to classical PPAR reference agonists, i.e., fenofibrate,
rosiglitazone, and GW501516. As shown in Table 1, PPARα/
δ/γ activation profile of GFT1803 is equilibrated in terms of
EC50 values (10–70 nM). The maximal efficacy for each of
PPAR isoform (Emax) is in the range of 57 to 84 % of the Emax
value of the corresponding reference compound.
GFT1803 was also optimized to provide a significant cen-
tral exposure upon oral administration. The central pharma-
cokinetic profile of GFT1803 at two different doses was
established in the Swiss mice model and compared to that of
pioglitazone (Fig. 1b, c). The central exposure of pioglitazone
(30 mg/kg) was 3.57 times higher as compared to GFT1803
(10 mg/kg) and 50 times higher as compared to GFT1803
(1 mg/kg) (Fig. 1b, Table 2). However, both compounds
showed similar brain/plasma partitioning ratio of 0.27–0.35
(Table 2).
GFT1803 Reduces Aβ Deposition and Neuroinflammation
in APP/PS1 Mice
To test the efficacy of GFT1803 on amyloid pathology in an
AD mouse model, we treated APP/PS1 mice for a period of
8 weeks, starting at the age of 4 months (Fig. 1a). GFT1803
and pioglitazone were both included in regular chow pellets to
yield daily drug regimens of 1 mg/kg (GFT1803), 10 mg/kg
(GFT1803), and 50 mg/kg (pioglitazone), with respect to an
average daily food intake rate.
We differentiated the pools of Aβ in the forebrain by
sequential extraction of brain homogenates starting with
radioimmunoprecipitation assay buffer (RIPA), followed by
2 % SDS and finally by 70 % formic acid. Fractions were
analyzed by multiplex ELISA for Aβ38, Aβ40, and Aβ42.
We observed no effect of drug treatments on Aβ 40 and 42
species in the RIPA-soluble fractions (Fig. 1d). Aβ38 concen-
trations were below the detection limit. In the SDS-soluble
fractions, treatment with GFT1803 (10 mg/kg) resulted in a
modest but significant decrease of both Aβ38 and Aβ40
species (Fig. 1e). Pioglitazone showed no effect on Aβ in
both RIPA and SDS-soluble fractions. Finally, the analysis of
the most insoluble Aβ pool after formic acid extraction
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(Fig. 1f) revealed a strong and dose-dependent reduction for
all three Aβ peptides in mice treated with GFT1803 (1 and
10 mg/kg). Treatment with pioglitazone (50 mg/kg) reduced
both Aβ38 and Aβ40 in formic acid-soluble fractions with
efficacy comparable to that of GFT1803 at 1 mg/kg, but had
no statistically significant effect on Aβ42.
Further, we analyzed brain sections stained with the amy-
loid dye, methoxy-XO4 and by immunostaining for Aβ (IC16
antibody) and for the microglial marker Iba1. Aβ deposits
were smaller and Iba1-immunoreactivity was decreased in
sections from GFT1803 treated mice (Fig. 2a). Quantification
of methoxy-XO4-positive plaques in samples frommice treat-
ed with GFT1803 (10 mg/kg) revealed a reduction of 48.5 %
in the cortex and a reduction of 32 % in the hippocampus
(Fig. 2b, c). However, no effect was observed for mice treated
with either pioglitazone or with GFT1803 at 1 mg/kg. Deter-
mination of the Aβ-covered area by immunohistochemistry
showed that GFT1803 (both doses) strongly reduced the Aβ
load in the cortex (34 % for 1 mg/kg and 42 % for 10 mg/kg)
and hippocampus (20 % for 1 mg/kg and 39 % for 10 mg/kg)
(Fig. 2a, d, e). Anti-inflammatory activities of PPARs were
extensively described in diverse systems, including the CNS.
Therefore, we investigatedmicroglial activation status in brain
sections by using the activation marker Iba1. The quantifica-
tion of the Iba1-covered area in the cortex showed a reduction
of 43 % in mice treated with GFT1803 at 1 mg/kg and a
reduction of 57 % in mice treated with GFT1803 at 10 mg/kg,
but no effect for mice treated with pioglitazone (Fig. 2f, g).
Similarly, the number of microglia per section was reduced in
both cortex (42 % for 1 mg/kg and 57 % for 10 mg/kg) and to
a lesser extent in hippocampus (38 % for 10 mg/kg), again
with no effect in the pioglitazone treatment group (Fig. 2h, i).
Western blot analysis of RIPA-extracted forebrain homog-
enates revealed no changes in APP expression (Fig. 3a–c), nor
in the α- and β-CTFs to APP ratio, suggesting unchanged
APP processing (Fig. 3a, d, e). In contrary, we observed a
reduction of Aβ in the FA and SDS fractions (Fig. 3a, f, g),
which confirmed the ELISA results. The expression of the
glial fibrillary acidic protein (GFAP), which is considered as
an astrocytic activation marker and therefore indicator of glial
inflammation, was found to be increased in APP/PS1 animals
as compared to wild-type mice, whereas treatment with either
GFT1803 or pioglitazone brought GFAP levels back to the
level observed in wild-type mice (Fig. 3a, h). Since ApoE is
implicated in Aβ removal [30, 31], we also tested if its
expression was modulated in brains of treated mice, but ApoE
expression remained stable (Fig. 3a, i). Interestingly, we ob-
served that treatment with GFT1803 but not with pioglitazone
induced the expression of the insulin-degrading enzyme
(IDE), a key protease, able to degrade Aβ (Fig. 3a, j).
These data demonstrate that in APP/PS1 mice, the effect of
GFT1803 on diverse AD pathology parameters was quantita-
tively and/or qualitatively superior as compared to pioglita-
zone. More specifically, GFT1803 performed better in reduc-
ing both highly insoluble (FA pool) and to a smaller extent
moderately insoluble (SDS pool) Aβ peptides and also curbed
microglial activation, which was not obtained by pioglitazone
treatment at the applied dosage.
GFT1803 Improves Spatial Learning and Memory
in APP/PS1 Mice
We used the Morris water maze paradigm to evaluate the
effect of GFT1803 treatment on hippocampal memory forma-
tion. As expected, wild-type mice performed best according to
latency and distance, whereas APP/PS1 mice showed impair-
ments for both parameters (204 and 183 % area under the
curve (AUC) increase for latency and distance, respectively)
(Fig. 4a–e). Treatment with both doses of GFT1803 reduced
latency (25 % for 1 mg/kg and 34 % for 10 mg/kg vs. APP/
PS1; AUC) as well as the distance swum (34 % for 1 mg/kg
and 33 % for 10 mg/kg vs. APP/PS1; AUC). Pioglitazone in
turn improved these parameters only in tendency. The probe
trial demonstrated that none of the groups failed to form
spatial memory (Fig. 4f). This indicates that GFT1803 im-
proves spatial learning and/or memory retention in APP/PS1
mice.
Next, we assessed context-dependent habituation to a novel
environment in the open field. APP/PS1 mice showed higher
activity and less habituation than wild-type mice. Importantly,
mice treated with 10 mg/kg GFT1803 habituated faster and
more completely than APP/PS1 mice, suggesting improved
contextual learning (Fig. 4g). We did not observe effects
treating with the lower dose of GFT1803 or pioglitazone.
Table 1 Transactivation assays in COS-7 cells
Gal4-PPARα (LBD) Gal4-PPARγ (LBD) Gal4-PPARδ (LBD)
EC50 (μM) TOP (% ref) EC50 (μM) TOP (% ref) EC50 (μM) TOP (% ref)
Murine 0.02 78 0.01 65 0.01 84
Human 0.03 57 0.06 61 0.07 84
Transactivation assays were performed in COS-7 cells. The Emax effect of GFT1803 is calculated relative to the maximal induction obtained with the
corresponding reference compound in the same experiment. The reference compounds for PPARα, PPARγ, and PPARδ were fenofibrate (100 μM),
rosiglitazone (10 μM), and GW501516 (1 μM), respectively
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Fig. 1 Experimental procedures,
pharmacokinetics, and Aβ
ELISA. a Scheme of the
experimental procedures. Mice
were treated from the age of
4–6 months with either GFT1803
or pioglitazone. At the beginning
of month 6, mice were tested in
the Morris water maze and in the
open field paradigm for a total
of 9 days. Drug treatment was
continued during this time.
Finally, mice were sacrificed
and brains were subjected to
histological analysis.
b Pharmacokinetics of GFT1803
and pioglitazone in Swiss mice.
Compounds were administered
by oral gavage (GFT1803 at 1 and
10 mg/kg; pioglitazone at
30 mg/kg) and their brain
concentrations were measured
throughout 24 h (mean ±SD).
c Determination of the area under
the curve (AUC) values after 24 h
of long exposure to the drugs.
d Quantification of RIPA-soluble
Aβ38, 40, and 42 from APP/PS1
mice treated with placebo
(control), 1 mg/kg GFT1803,
10 mg/kg GFT1803, or 50 mg/kg
pioglitazone (pio) by multiplex
ELISA. Aβ38 could not be
detected in this fraction. e Same
as (d) but for SDS-soluble Aβ38,
40, and 42. f Same as (d) but for
formic acid-soluble Aβ38, 40,
and 42 (mean of n=11 for control,
n=9 for pio, n=12 for 1 mg/kg
GFT1803, and n=11 for
10 mg/kg GFT1803 ±SEM;
one-way ANOVA, Tukey post
hoc test; *p<0.05, **p<0.01,
***p<0.001)
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Discussion
In this study, we provide a comprehensive analysis of the new
pan-PPAR agonist GFT1803 for its impact on receptor acti-
vation, plaque burden, neuroinflammation, and spatial mem-
ory in a murine model of Alzheimer’s disease (AD). Previous
studies have shown beneficial effects of PPARγ activation in
several animal models of neurological disease [10], including
cerebral ischemia [23], multiple sclerosis [32], Parkinson’s
disease [33], and AD [12]. These experimental studies primar-
ily used agonists of the thiazolidinedione class of antidiabetic
drugs (TZDs), which were developed for the treatment of non-
Table 2 Values that correspond to the mean plasma and brain 24-h AUC (ng/h*ml)
AUC [24 h] Brain (ng×h−1×ml−1) AUC [24 h] Plasma (ng×h−1×ml−1) Brain/plasma ratio
GFT1803 (1 mg/kg) 1,921 6,065 0.32
GFT1803 (10 mg/kg) 24,249 88,854 0.27
Pio (30 mg/kg) 88,112 252,551 0.35
In relative numbers, the central exposure to pioglitazone (30 mg/kg) was roughly 50 times higher as compared to GFT1803 (1 mg/kg) and
roughly 3.57 times higher as compared to GFT1803 (10 mg/kg). Both compounds showed similar brain/plasma partitioning ratio of 0.27–0.35
(AUC area under the curve)
Fig. 2 Histological analysis.
a Brain section of APP/PS1 mice
treated with placebo (control),
1 mg/kg GFT1803, 10 mg/kg
GFT1803, or 50 mg/kg
pioglitazone (pio) were stained
with the amyloid dye methoxy-
XO4 followed by immunostaining
using antibodies IC16 against Aβ
and the antibody anti-Iba1 to
detect microglia. b Quantification
of methoxy-XO4-positive plaques
in the cortex and c in the
hippocampus. d Determination of
Aβ-covered area using antibody
IC16 in the cortex and e in the
hippocampus. f Determination of
Iba1-covered area using antibody
anti-Iba1 in the cortex and g in the
hippocampus. h Quantification of
Iba1-positive microglia in the
cortex and i in the hippocampus
(mean of n=5 for control, n=5 for
pio, n=6 for 1 mg/kg GFT1803,
and n=7 for 10 mg/kg GFT1803
±SEM; one-way ANOVA, Tukey
post hoc test; *p<0.05, **p<0.01,
***p<0.001)
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Fig. 3 Biochemical analysis.
a Immunoblot analysis of APP
and APP-CTF in forebrain
samples using antibody CT15,
APP and Aβ using antibody
6E10, GFAP, IDE, ApoE, and
tubulin. Densiometric
quantification of b APP using
CT15, c of APP/sAPPα using
antibody 6E10, d α-CTF/APP
using antibody CT15, e β-CTF/
APP using antibody CT15, f Aβ
in the SDS fraction, g Aβ in the
FA fraction, h GFAP i of ApoE,
j and of IDE (b–g are mean of
n=5 ±SEM, one-way ANOVA,
Tukey post hoc test; *p<0.05,
**p<0.01, ***p<0.001)
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insulin dependent type 2 diabetes. Since TZDs have recently
come under scrutiny for their potential cardiovascular side
effects, some of these drugs are not longer considered as
possible interventional therapeutics [34]. Positive reports of
agonists activating other PPAR isoforms, which reduced Aβ
plaque burden [22] and concomitant neuroinflammation [35]
lead to the development of novel pan-PPAR ligands. Current
characterization of these substances suggests they may dem-
onstrate better benefit/risk ratios due to a balanced activation
of all three PPAR isoforms, while at the same time keeping the
positive properties reported for single receptor activation.
In the present study, preventive treatment of APP/PS1 mice
with GFT1803 was initiated well before the onset of plaque
deposition and strikingly suppressed Aβ deposition at later
stages. Analyzing brain homogenates, the strongest reduction
was observed in the extremely insoluble formic acid fraction
of Aβ. This finding suggests that either the formation of Aβ
deposits were efficiently prevented or the removal was specif-
ically stimulated. The latter hypothesis is supported by recent
findings showing that PPAR activation increased microglial
clearance through CD36-dependent phagocytosis [36]. Given
recent evidence that reduced Aβ clearance accounts for the
majority of AD cases of sporadic nature [37], increasing
microglial clearance through pan-PPARmodulation may offer
a novel therapeutic strategy. Immunohistological analysis of
the effect of pioglitazone on Aβ deposition revealed minor
changes, whereas the ELISA results show a strong decrease in
the FA fraction. This might be due to the fact that both
methods do no describe the exact same pool of Aβ.
In AD, Aβ deposition and neuronal demise activate mi-
croglia through several surface molecules including toll-like
receptors [38], which subsequently leads to the production
and release of proinflammatory molecules including cyto-
kines, chemokines, nitric oxide, and prostaglandins. This
acute and sterile inflammatory action may initially serve the
attempt to maintain cerebral homeostasis and increase clear-
ance capacity of microglia. While usually this type of inflam-
mation rapidly resolves upon pathogen removal, ongoing
deposition of Aβ does not allow for resolution but leads to a
chronic type of cerebral inflammation. Furthermore, a chronic
proinflammatory environment is able to upregulate neuronal
BACE1 thereby further fueling APP processing and Aβ gen-
eration [22, 39]. Likewise, inflammation-driven induction of
NOS2 which goes along with massive production of nitric
oxide induces the nitration-induced aggregation of Aβ in
senile plaques [40].
Fig. 4 Behavioral analysis. Spatial memory learning of APP/PS1 mice
treated with placebo (control), 1 mg/kgGFT1803, 10mg/kgGFT1803, or
50 mg/kg pioglitazone (pio) in the Morris water maze. a Time needed to
reach the hidden platform (latency in seconds). b Integrated time to reach
the platform (area under the curve). cDistance traveled (in centimeters). d
Integrated distance traveled (area under the curve). e Setup of the Morris
water maze (Q1–4 quadrant 1–4). f Mice were tested 1 day after the last
trial day for 30 s in the absence of the platform. The time in the quadrants
was measured and averaged for quadrants 2–4 (Q1-4 av.) (mean of n=11
for control, n=9 for pio, n=12 for 1 mg/kg GFT1803, and n=11 for
10 mg/kg GFT1803 ±SEM, Student’s t test, **p<0.01, ***p<0.001). g
Distance traveled (in centimeters) in the open field assessment (mean of
n=11 for control, n=9 for pio, n=12 for 1 mg/kgGFT1803, and n=11 for
10 mg/kg GFT1803 ±SEM; one-way ANOVA, Tukey post hoc test;
*p<0.05, **p<0.01, ***p<0.001)
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Based on the overall detrimental action of chronic
neuroinflammation, inhibitory interventions are sought.
Preventive GFT1803 treatment of APP/PS1 mice reduced
microglial immunoreactivity, suggesting suppression of the
neuroinflammatory component in this model. Most likely,
this anti-inflammatory action is due to activation of all
three PPAR isoforms and not mediated by a single receptor,
since all PPARs have been shown to exert anti-inflammatory
action. Thus, PPARγ activation results in strong suppression
of inflammation by transcriptional transrepression of NFκB
[41]. This anti-inflammatory action of PPARγ ligands was
shown to be neuroprotective in several experimental models
of neuroimmunological and neurodegenerative disease
[12, 23, 32, 33]. Likewise, the PPARα agonist fenofibrate
protected neurons and axons against micro- and astroglia-
derived nitric oxide-mediated toxicity in vitro and inhibited
the secretion of the proinflammatory cytokines IL-1β,
TNF-α, IL-6, and IL-12 p40 34, 35. Additionally, PPARα
induces transcription of genes of the β- and ω-oxidation
pathways that neutralize and degrade LTB4, a powerful che-
motactic inflammatory eicosanoid, to regulate the inflamma-
tory response [42]. Administration of GW0742, a potent
PPARδ-selective agonist, significantly reduced amyloid
plaque burden in the subiculum of 5xFAD mice, which was
associated with decreased glial activation and increased ex-
pression of neprilysin, an amyloid-degrading, microglia-
derived enzyme [22]. The antioxidant and anti-inflammatory
actions of PPARδ agonists have been observed in a variety of
cell types, including astrocytes and microglia. In particular,
PPARδ can activate transcription of antioxidant genes, includ-
ing catalase and superoxide dismutase [43, 44]. The improved
learning and memory phenotype found in response to the
treatment with GFT1803 is likely to arise of a combination
of the above described Aβ-reducing and anti-inflammatory
effects, as both, Aβ and inflammatory molecules have been
shown to suppress memory relevant neurophysiological pro-
cesses such as hippocampal long-term potentiation [45, 46]. In
most of the parameters analyzed in this study, GFT1803 was
superior when compared to treatment with the TZD pioglita-
zone at drug concentrations previously investigated in models
of neurodegeneration.
Currently, the pioglitazone is tested in a phase III study to
evaluate the efficacy of a long-term treatment with low-dose
pioglitazone in delaying the onset of MCI in cognitively
normal individuals at high risk. Even so, we did not detect
strong effects in our mouse model, long-term, low-dose treat-
ment with pioglitazone might still be effective.
Even so, we cannot rule out that the superior efficacy of
GFT1803 was caused by yet non-described off-target effects,
unrelated to the activation of PPARs; one might consider that
targeting all three PPAR isoforms may represent a successful
strategy to suppress cerebral amyloidosis and chronic inflam-
mation. The data presented here identify GFT1803 as a highly
efficient PPAR agonist, which prevents the development of
pathological and behavioral hallmarks of AD in the AP/PS1
mouse model when given from early time points on. Further
studies have to prove now whether these promising data hold
true in human AD.
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